Sign Out
No interaction study has been performed.
Ceftriaxone must not be co-administered with IV solutions containing calcium, because of the risk of precipitation of ceftriaxone-calcium salt. If the same infusion line is used for sequential administration, the line must be thoroughly flushed between infusions with a compatible fluid (e.g. physiological salt solution) to avoid precipitation.
OliClinomel contains vitamin K, naturally present in lipid emulsions. The vitamin K content in the recommended doses of OliClinomel should not have any effect on the effects of coumarin derivatives, including warfarin.
This emulsion for infusion must not be administered simultaneously with blood through the same infusion tubing because of the risk of pseudoagglutination.
The lipids contained in this emulsion may interfere with the results of certain laboratory tests (for example bilirubin, lactate dehydrogenase, oxygen saturation, blood haemoglobin) if the blood sample is taken before the lipids have been eliminated (these are generally eliminated after a period of 5 to 6 hours without receiving lipids).
Because of the potassium content in OliClinomel, it is advisable to exercise caution in patients treated with potassium-sparing diuretics (e.g. amiloride, spironolactone, triamterene), angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine in view of the risk of HYPERkalemia.
